Division of Rheumatology, Department of Medicine, University of Toronto, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, 399 Bathurst Street, 1E-410B, Toronto, Ontario M5T 2S8, Canada.
Curr Rheumatol Rep. 2010 Aug;12(4):288-94. doi: 10.1007/s11926-010-0107-0.
Biomarkers in psoriatic arthritis (PsA) may serve as surrogate end points for disease outcome and can provide insights into disease susceptibility and natural history. Biomarkers could relate to diagnosis, pathogenesis, prognosis, therapeutic response, and comorbidities. The "felt need" is, however, in the development of biomarkers for the presence of PsA in patients with psoriasis, as well as that for joint damage. During the past few years, many studies related to PsA biomarkers have been conducted. These studies are reviewed here. C-reactive protein, matrix metalloproteinase-3, and circulating osteoclast precursors show promise. An international goal-directed study to determine biomarkers for joint damage in PsA is now under way through a collaborative effort of GRAPPA (the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis) and OMERACT (Outcome Measures for Rheumatology Clinical Trials).
银屑病关节炎（PsA）的生物标志物可作为疾病结局的替代终点，有助于深入了解疾病易感性和自然病程。生物标志物与诊断、发病机制、预后、治疗反应和合并症相关。目前，人们迫切需要开发用于银屑病患者中存在 PsA 以及关节损伤的生物标志物。在过去几年中，已经进行了许多与 PsA 生物标志物相关的研究。本文对这些研究进行了综述。C 反应蛋白、基质金属蛋白酶 3 和循环破骨细胞前体具有一定的应用前景。目前，GRAPPA（银屑病和银屑病关节炎研究评估组）和 OMERACT（风湿病临床试验结局测量）正在合作开展一项旨在确定 PsA 关节损伤生物标志物的国际目标导向研究。
